PLGA-PEG nanoparticles for targeted delivery of the mTOR/PI3kinase inhibitor dactolisib to inflamed endothelium

Keyphrases

• Acetyl 25%
• Anti-E 25%
• Anti-inflammatory Therapy 25%
• BEZ235 25%
• Blotting 25%
• Bovine Serum Albumin 25%
• Cell Functional Assays 25%
• Cellular Uptake 25%
• Confocal Microscopy Analysis 25%
• Conjugation 25%
• Dactolisib 100%
• Distal End 25%
• Drug Release Profile 25%
• Drug-polymer Interaction 25%
• E-selectin 100%
• Emulsion Solvent Evaporation 25%
• Encapsulation Efficiency 50%
• Endothelial Cells 75%
• Endothelium 100%
• In Vitro Release 25%
• Inflammation 25%
• Inflammatory Disorders 25%
• Mammalian Target of Rapamycin (mTOR) 100%
• Migration Assay 25%
• Nanomedicine 25%
• Nanoparticles 100%
• NVP-BEZ235 25%
• Oil-in-water Emulsion 25%
• Particle Size 25%
• Particle Size Distribution 25%
• PI3K Inhibitor 100%
• PI3K Signaling Pathway 25%
• PLGA-PEG 50%
• PLGA-PEG Nanoparticles 100%
• Poly(d,l-lactide-co-glycolide) 50%
• Polyethylene Glycol 25%
• Polymeric Nanoparticles 25%
• Targeted Delivery 100%
• Targeted Nanoparticles 75%
• Tumor Necrosis Factor-α 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Acetic Acid Derivative 10%
• Anti-Inflammatory Drug 10%
• Bovine Serum Albumin 10%
• Confocal Microscopy 10%
• Dactolisib 100%
• Drug Release 10%
• E-Selectin 40%
• Inflammation 10%
• Macrogol 2000 10%
• Nanomedicine 10%
• Nanoparticle 100%
• Particle-Size Distribution 10%
• Polyethylene Glycol 100%
• Rhesus E Antibody 10%
• Tumor Necrosis Factor 10%
• Water Oil Cream 10%